• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • Navigate Novartis
    • Patients
    • Healthcare Professionals
    • Media
    • Investors
    • Partners
    • ESG
    • Job Seekers
    • Clinical Trials
  • Coronavirus
  • Global
    • Novartis site directory
Novartis logo: a global healthcare company
  • Our Company
    • Our Leadership
      • Board of Directors
      • Executive Committee of Novartis
    • Our Approach
      • Strategy
      • Corporate Responsibility
      • Diversity & Inclusion
      • Partnering
      • People and Culture
    • Our Business
      • Global Product Portfolio
      • Innovative Medicines
      • Novartis Pharmaceuticals
      • Novartis Gene Therapies
      • Novartis Oncology
      • Sandoz
    • Media
      • Newsroom
      • News Archive
      • Multimedia Resources
      • Subscribe to Updates
    • Investors
      • Event Calendar
      • Financial Data
      • Share Data & Analysis
      • Shareholder Information
      • Environmental, Social & Governance
  • Our Focus
    • Disease Areas
      • Cancer
      • Cardiovascular, Renal and Metabolic Medicine
      • Immunology & Dermatology
      • Ophthalmology
      • Neuroscience
      • Respiratory
    • Platforms and Technology
      • Data and Digital
      • Cell & Gene Therapy
    • Novartis Stories
      • Discovery
      • From Our Labs
      • Access to Healthcare
      • Patient Perspectives
      • People and Culture
      • Live Magazine
  • Our Impact
    • Building Trust with Society
      • Corporate Responsibility
      • Ethical Standards
      • Access
      • Environmental Sustainability
    • Global Health
      • Malaria
      • Sickle Cell Disease
      • Chagas disease
      • Leprosy
      • Novartis Foundation
    • ESG Performance and Reporting
      • Materiality Assessment
      • Environmental, Social and Governance
      • Transparency and Disclosures
      • Positions on Key Topics
      • Statements on Key Issues
  • Our Science
    • Research & Early Development
      • Novartis Institutes for BioMedical Research
      • Research Disease Areas
      • Postdoc Program
      • Open Source Science
    • Drug Development at Novartis
      • Novartis Pipeline
      • Clinical Trials
      • Translational Medicine
      • Global Product Portfolio
    • Science Stories
      • Discovery
      • From Our Labs
  • Careers
    • Your Career
      • Global Career Search
      • Teams and Skills
      • Gene Therapies Careers
    • Working at Novartis
      • Diversity & Inclusion
      • People and Culture
      • Corporate Responsibility
    • Career Programs
      • Our Career Programs
      • Students and Scholars
      • Novartis Quantitative Sciences Hackathon
Search
  • TwitterTweet
  • FacebookShare
  • Share
    • Twitter
    • Facebook
    • LinkedIn
    • Email
    • Whatsapp
  • Jump to Comments
Stories/Discovery

Leveraging the liver’s ability to heal scarred tissue

A reversal in thinking about the reversibility of liver damage is changing the field of hepatology.

By
Elizabeth Dougherty
Feb 10, 2016

In medical school, Cliff Brass was interested in the brain. He and a friend, who favored the liver, used to argue about which organ was smarter. They are both hepatologists now. 

“I guess that answers that question,” says Brass, Senior Global Program Medical Director at Novartis Pharmaceuticals. “The liver is an amazing organ.” 

 Leveraging the liver’s ability to heal scarred tissue

For instance, it is possible to take a hunk of one person’s liver and transplant it into another person. The partial organ will grow to fit the space available, suggesting that the liver has unusual regenerative capabilities. 

It is one thing for a healthy liver to have such powers, but can a scarred liver heal itself? For a long time, the answer was quick and clear: No.  

“Despite the fact that evidence of the reversibility of liver scarring started accumulating in the 1960s, the prevailing wisdom was that once you get scar tissue in the liver, it’s permanent,” says Chinwe Ukomadu, a hepatologist and Senior Translational Medicine Specialist at the Novartis Institutes for BioMedical Research. 

Only recently have scientists and liver specialists begun to change their answer to a qualified yes. Yes, it’s reversible, but it isn’t clear how. This shift in thinking has opened the door to the idea that medicine may be able to speed up the process. Scarring occurs in many liver diseases and is ultimately the cause of liver failure in late stages of disease, so healing scarred liver tissue would benefit most liver disease patients. For instance, Novartis has recently begun clinical testing of a new investigational compound that might have anti-scarring effects.  

One of the first clues suggesting that liver scarring might be reversible came out of a hospital in Miami, FL, in 1962. Doctors there were working with a handful of patients with hemochromatosis, a disorder that causes iron to accumulate in the liver and cause scarring. They took biopsies of patients’ livers before and after performing procedures to remove the iron. After the procedure, they found that the amount of scarring had decreased. 

Over time, similar hints appeared in other small-scale studies, says Ukomadu. For instance, the life expectancies of recovering alcoholics—who are thought to have extensive liver scarring—are longer than the life expectancies of people who continue to drink. And patients with autoimmune hepatitis who are treated with steroids to reduce liver damaging inflammation have similar life expectancies whether they begin treatment with advanced liver scarring, called cirrhosis, or without. 

“In these cases, something is getting better,” says Ukomadu. “But is it the liver? Researchers have argued that it could be anything.” 

The real turning point in thinking came with the advent of treatments for viral liver disease. In the 1990s, drugs became available to treat hepatitis C and hepatitis B. When patients took these drugs, they effectively removed the root cause of the organ damage. Later, liver biopsies revealed that many patients, even those with late-stage cirrhosis had recovered. 

“In some cases, you couldn’t tell that the patients had been sick,” says Ukomadu. “Their cirrhosis had completely disappeared.” 

Today, researchers at Novartis see two possible ways to repair scarred livers. One is to stop the disease process that is causing the damage and wait for tissue to heal.  

This approach has merit, but during the time it takes for the liver to repair itself, patients are left in a vulnerable condition. If they experience another illness or hospitalization while living with an incapacitated liver, they may not fare well. In some cases, this vulnerability may be hidden because patients with liver scarring don’t always show symptoms.  

“The liver is a biochemical factory for the body, but it’s a factory with a vast overcapacity,” says Brass. “It may not be until someone’s liver is very close to the edge of keeping up that they suddenly see a dramatic downturn in health.” 

Currently the only option for patients with end-stage liver disease is a liver transplant. This procedure is only offered in certain parts of the world, and donor tissue is in short supply.  
So Novartis favors a more proactive strategy to find ways to directly reverse scarring to give liver disease patients a fighting chance. 

“Many patients who are waiting for transplants become miserably sick,” says Ukomadu. “The ability to stall or reverse liver scarring would have enormous impact.” 

Main image: This liver tissue from a patient with non-alcoholic fatty liver disease (NASH) shows mild fibrosis (green), which can lead to advanced liver scarring called cirrhosis. Image: Nephron/Wikimedia

Shareline

A reversal in thinking about the reversibility of liver damage is changing the field of hepatology.
Tweet Tweetpopo
Tags: 
Biomedical Research, Novartis Institutes for BioMedical Research, Clinical Science, Drug Design

Elizabeth Dougherty

Elizabeth Dougherty

is a science writer at the Novartis Institutes for BioMedical Research.

    • TwitterTweet
    • FacebookShare
    • Share
      • Twitter
      • Facebook
      • LinkedIn
      • Email
      • Whatsapp
    • Jump to Comments
  • Print
  • Save

Novartis Stories

View all

RNA strand
Discovery

Take a visual tour of medicines that target RNA

A kidney patient is smiling at the camera
Discovery

New hope for treating inflammatory diseases of the kidney

2D rendering of kidneys
Discovery

Predictive analytics could bring medicines to patients faster

You are here

  1. Home ›
  2. Stories ›
  3. Discovery

Novartis Global

  • Navigate Novartis

    • Patients & Caregivers
    • Healthcare Professionals
    • Investors
    • Media
    • Society & ESG
    • Partners
  • Contact Us

    • Global Contacts
    • Office Locations
    • For Investors
    • For Media
  • About Novartis

    • Our Company
    • Our Focus
    • Our Impact
    • Our Science
    • Our Stories
  • Our Portfolio

    • Global Product Portfolio
    • Global Clinical Pipeline
  • Careers

    • Career Search

Connect with Novartis

  • twitter
  • linkedin
  • youtube
  • facebook
  • instagram
Novartis Site Directory
© 2021 Novartis AG
  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Site Map
  • Cookie Settings

This site is intended for a global audience.